MCID: MSC004
MIFTS: 27

Muscle Tissue Disease

Categories: Muscle diseases

Aliases & Classifications for Muscle Tissue Disease

MalaCards integrated aliases for Muscle Tissue Disease:

Name: Muscle Tissue Disease 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:66

Summaries for Muscle Tissue Disease

MalaCards based summary : Muscle Tissue Disease is related to malignant hyperthermia and rippling muscle disease 1. An important gene associated with Muscle Tissue Disease is DMD (Dystrophin), and among its related pathways/superpathways are DREAM Repression and Dynorphin Expression and Dilated cardiomyopathy (DCM). The drugs Benzocaine and Entecavir have been mentioned in the context of this disorder. Affiliated tissues include brain and eye, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Muscle Tissue Disease

Diseases related to Muscle Tissue Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 91)
# Related Disease Score Top Affiliating Genes
1 malignant hyperthermia 31.5 DMD LAMA2 PIK3C2A RYR1
2 rippling muscle disease 1 10.7
3 rippling muscle disease 2 10.7
4 distal arthrogryposis 10.7
5 myostatin-related muscle hypertrophy 10.7
6 myotonia congenita 10.7
7 localized lipodystrophy 10.4 DMD DYSF
8 cytoplasmic body myopathy 10.4 DMD UTRN
9 survival motor neuron spinal muscular atrophy 10.3 SMN1 SMN2
10 oculopharyngodistal myopathy 10.3 GNE PABPN1
11 charcot-marie-tooth disease, dominant intermediate b 10.3 MTM1 RYR1
12 autosomal recessive limb-girdle muscular dystrophy type 2g 10.3 CAPN3 DYSF
13 arthrogryposis multiplex congenita, neurogenic type 10.3 SMN1 SMN2
14 spinal muscular atrophy, type iii 10.3 SMN1 SMN2
15 spinal muscular atrophy, type ii 10.3 SMN1 SMN2
16 culler-jones syndrome 10.3 SMN1 SMN2
17 anterior compartment syndrome 10.3 DYSF PIK3C2A
18 juvenile spinal muscular atrophy 10.3 SMN1 SMN2
19 centronuclear myopathy 10.3 DMD MTM1 RYR1
20 spinal muscular atrophy, type iv 10.3 MSTN SMN1 SMN2
21 cardiomyopathy, dilated, 1d 10.3 DAG1 DMD LAMA2
22 paresthesia 10.3 CAPN3 FKRP
23 congenital muscular dystrophy without intellectual disability 10.3 FKRP FKTN
24 autosomal genetic disease 10.3 DMD RYR1 UTRN
25 brody myopathy 10.3 CLCN1 DMD RYR1
26 autosomal recessive limb-girdle muscular dystrophy type 2j 10.3 CAPN3 FKRP
27 spinal muscular atrophy, distal, autosomal recessive, 1 10.3 SMN1 SMN2
28 myopathy, proximal, and ophthalmoplegia 10.3 EMD RYR1
29 bethlem myopathy 1 10.3 CAPN3 DMD DYSF
30 arthrogryposis, distal, type 1a 10.3 RYR1 SMN1
31 autosomal recessive limb-girdle muscular dystrophy type 2f 10.3 CAPN3 DYSF SGCA
32 autosomal recessive limb-girdle muscular dystrophy type 2h 10.3 CAPN3 FKRP
33 central core myopathy 10.3 MTM1 RYR1
34 chromosome xp21 deletion syndrome 10.3 DMD PIK3C2A
35 creatine phosphokinase, elevated serum 10.3 DMD LAMA2 PIK3C2A
36 polyglucosan body myopathy 1 with or without immunodeficiency 10.3 CAPN3 DMD FKRP
37 peripheral nervous system disease 10.3 MTM1 SMN1 SMN2
38 cardiomyopathy, dilated, 3b 10.3 DMD SGCA
39 rigid spine muscular dystrophy 1 10.3 DMD DYSF LAMA2 RYR1
40 muscular dystrophy-dystroglycanopathy , type c, 4 10.3 FKRP FKTN
41 myopathy, congenital 10.3 DMD DYSF MTM1 RYR1
42 muscular dystrophy, limb-girdle, autosomal recessive 8 10.3 CAPN3 DYSF FKRP
43 myopathy, tubular aggregate, 1 10.3 EMD PABPN1 RYR1
44 muscle disorders 10.3 CLCN1 PIK3C2A RYR1
45 autosomal recessive limb-girdle muscular dystrophy type 2l 10.3 DYSF FKRP FKTN
46 cardiomyopathy, dilated, 1b 10.3 DAG1 DMD FKTN LAMA2
47 autosomal dominant limb-girdle muscular dystrophy type 1c 10.3 DYSF FKRP MSTN
48 autosomal recessive limb-girdle muscular dystrophy type 2c 10.3 CAPN3 DMD DYSF SGCA
49 congenital fiber-type disproportion 10.3 DMD DYSF EMD RYR1
50 autosomal recessive limb-girdle muscular dystrophy type 2b 10.3 CAPN3 DMD DYSF SGCA

Graphical network of the top 20 diseases related to Muscle Tissue Disease:



Diseases related to Muscle Tissue Disease

Symptoms & Phenotypes for Muscle Tissue Disease

GenomeRNAi Phenotypes related to Muscle Tissue Disease according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.25 CAPN3 PIK3C2A
2 Decreased viability GR00221-A-1 10.25 GNE PIK3C2A
3 Decreased viability GR00221-A-2 10.25 PIK3C2A
4 Decreased viability GR00221-A-3 10.25 GNE
5 Decreased viability GR00221-A-4 10.25 DYSF GNE PIK3C2A
6 Decreased viability GR00240-S-1 10.25 CLCN1 PIK3C2A SMN2
7 Decreased viability GR00301-A 10.25 DYSF
8 Decreased viability GR00342-S-1 10.25 PIK3C2A
9 Decreased viability GR00342-S-2 10.25 PIK3C2A
10 Decreased viability GR00342-S-3 10.25 PIK3C2A
11 Decreased viability GR00381-A-1 10.25 FKRP LAMA2 SGCA
12 Decreased viability GR00402-S-2 10.25 CAPN3 CLCN1 DAG1 DMD DYSF EMD
13 no effect GR00402-S-1 9.62 CAPN3 CLCN1 DAG1 DMD DYSF EMD

MGI Mouse Phenotypes related to Muscle Tissue Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.38 CLCN1 DAG1 DMD DYSF EMD FKRP
2 homeostasis/metabolism MP:0005376 10.32 CAPN3 CLCN1 DAG1 DMD DYSF EMD
3 cardiovascular system MP:0005385 10.27 CAPN3 DAG1 DMD EMD FKRP GNE
4 growth/size/body region MP:0005378 10.25 CAPN3 CLCN1 DAG1 DMD FKRP FKTN
5 cellular MP:0005384 10.21 DAG1 DMD EMD FKRP FKTN LAMA2
6 muscle MP:0005369 10.11 CAPN3 CLCN1 DAG1 DMD DYSF EMD
7 mortality/aging MP:0010768 10.1 CLCN1 DAG1 DMD FKRP FKTN GNE
8 immune system MP:0005387 10.02 DMD DYSF FKRP FKTN GNE LAMA2
9 no phenotypic analysis MP:0003012 9.5 CAPN3 CLCN1 DMD DYSF MSTN MTM1
10 skeleton MP:0005390 9.28 CLCN1 DMD FKRP LAMA2 MSTN MTM1

Drugs & Therapeutics for Muscle Tissue Disease

Drugs for Muscle Tissue Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 786)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
2
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
3 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
5
Pirfenidone Approved, Investigational Phase 4 53179-13-8 40632
6
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 302-25-0
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-24-8 5755
8
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2921-57-5
9
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 83-43-2 6741
10
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 16590-41-3 5360515
11
Milnacipran Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 92623-85-3 65833
12
Etoricoxib Approved, Investigational Phase 4,Phase 3,Phase 1 202409-33-4 123619
13
Ramipril Approved Phase 4 87333-19-5 5362129
14
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
15
Amitriptyline Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-48-6 2160
16
Cyclobenzaprine Approved Phase 4,Phase 3,Phase 2,Not Applicable 303-53-7 2895
17
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
18
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 56-12-2 119
19
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 60142-96-3 3446
20
Perphenazine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-39-9 4748
21
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 124-94-7 31307
22
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
23
Sodium oxybate Approved Phase 4,Phase 3,Phase 2 502-85-2 5360545
24
Dinoprostone Approved Phase 4,Not Applicable 363-24-6 5280360
25
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
26
Bezafibrate Approved, Investigational Phase 4,Phase 3,Phase 2 41859-67-0 39042
27
Simvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 79902-63-9 54454
28
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
29
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
30
Polidocanol Approved Phase 4,Phase 2 9002-92-0
31
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 148553-50-8 5486971
32
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
33
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-41-2 439260
34
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2 27203-92-5 33741
35
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 103-90-2 1983
36
Ibuprofen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15687-27-1 3672
37
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 525-66-6 4946
38
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
39
Baclofen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1134-47-0 2284
40
Azathioprine Approved Phase 4,Not Applicable 446-86-6 2265
41
Colchicine Approved Phase 4,Phase 3,Not Applicable 64-86-8 6167 2833
42
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 378-44-9 9782
43
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 9004-61-9 53477741
44
Ethanol Approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
45
Dronabinol Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1972-08-3 16078
46
Doxycycline Approved, Investigational, Vet_approved Phase 4,Not Applicable 564-25-0 54671203
47
Citalopram Approved Phase 4,Phase 3,Not Applicable 59729-33-8 2771
48
Abatacept Approved Phase 4,Phase 3,Phase 2,Early Phase 1 332348-12-6 10237
49
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 175805 71273
50
Nitroglycerin Approved, Investigational Phase 4,Phase 2,Not Applicable 55-63-0 4510

Interventional clinical trials:

(show top 50) (show all 3066)
# Name Status NCT ID Phase Drugs
1 Identification of Carnitine-Responsive Cardiomyopathy Unknown status NCT01904396 Phase 4 Carnitine
2 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
3 Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences. Unknown status NCT02033057 Phase 4
4 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
5 6-Methyl-Prednisolone for Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
6 A Randomized Trial to Evaluate the Effectiveness of Transferring the Flexor Hallucis Longus Tendon Unknown status NCT01341509 Phase 4
7 Low Dose Naltrexone for Treatment of Pain in Patients With Fibromyalgia - Effect Via a Central Mechanism? Unknown status NCT02806440 Phase 4 Low dose naltrexone;Placebo
8 Study of Fibromyalgia Treated With Milnacipran Unknown status NCT01125423 Phase 4 Milnacipran
9 Study Assessing the Efficacy of Etoricoxib in Female Patients With Fibromyalgia Unknown status NCT00755521 Phase 4 etoricoxib
10 The Study of Using Esophageal Pressure to Guide the PEEP Setting in Abdominal Hypertension Patients Who Undergoing Mechanical Ventilation Unknown status NCT01825304 Phase 4
11 Ramipril Versus Carvedilol in Duchenne and Becker Patients Unknown status NCT00819845 Phase 4 carvedilol;ramipril
12 The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy Unknown status NCT00606775 Phase 4 Carvedilol
13 Cyclobenzaprine Extended Release (ER) for Fibromyalgia Unknown status NCT01041495 Phase 4 cyclobenzaprine ER (AMRIX);placebo
14 Meditoxin® Treatment in Patients With Post Stroke Upper Limb Spasticity Unknown status NCT02757404 Phase 4
15 Prospective, Cross Over Gabapentin vs Amitriptyline Study on Patients Suffering From Masticatory Muscle Pain Unknown status NCT02339662 Phase 4 Gabapentin;Amitriptyline
16 Upper Extremity Rehabilitation Using Robot and Botulinum Toxin Unknown status NCT02228863 Phase 4
17 Corticosteroid Injection Verses High Energy Extracorporeal Shock Wave Therapy for Lateral Epicondylitis Unknown status NCT02613455 Phase 4 Kenalog (triamcinolone);lidocaine 1% (lidocaine HCl 20mg)
18 The Effectiveness of Early Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults Unknown status NCT02505802 Phase 4 BoNT-A injection
19 Effects of Functional Electrical Stimulation on Gait in Children With Cerebral Palsy Unknown status NCT02462018 Phase 4
20 Sodium Oxybate in Patients With Chronic Fatigue Syndrome. Unknown status NCT01584934 Phase 4 Sodium oxybate;Placebo
21 Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity Unknown status NCT02358005 Phase 4
22 Evaluation of the Effects of L-Carnitine Injection in Patients Undergoing Hemodialysis Unknown status NCT00173706 Phase 4 L-Carnitine Injection
23 Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke Unknown status NCT02114736 Phase 4 Botulinum Toxin injection in the rectus femoris muscle
24 The Efficacy and Safety of MEDITOXIN® in Children With Cerebral Palsy Unknown status NCT01256021 Phase 4 Botulinum Toxin Type A
25 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
26 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
27 Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis Unknown status NCT01400464 Phase 4 Prednisone therapy and pharmacokinetic
28 Nasal Continuous Positive Airway Pressure (CPAP) in Chronic Fatigue and Sleep-disordered Breathing Unknown status NCT01368718 Phase 4
29 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
30 The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM) Completed NCT01527318 Phase 4 Fibrate treatment
31 Differences in Atorvastatin Metabolite Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity Completed NCT00199745 Phase 4 atorvastatin
32 Association Between Systemic Exposure of Atorvastatin and Metabolites and Atorvastatin-induced Myotoxicity Completed NCT00120055 Phase 4 Atorvastatin (Lipitor)
33 Investigations on Differences in Atorvastatin Metabolites Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity Completed NCT00414531 Phase 4 Atorvastatin
34 Using Clonidine to Improve Leg Weakness in People With Heart Failure Completed NCT00858845 Phase 4 Clonidine Patch
35 Two Different Dosages of Nebulized Steroid Versus Parenteral Steroid in the Management of COPD Exacerbations Completed NCT01865500 Phase 4 Budesonide 4 mg;Budesonide 8 mg;Metil prednisolone
36 Effects of Vitamin D Supplementation in Obesity Completed NCT01037140 Phase 4 Cholecalciferol;placebo
37 Effect of Gemfibrozil on the Safety and Pharmacokinetics of Red Yeast Rice in Healthy Subjects Completed NCT01385020 Phase 4 Gemfibrozil & red yeast rice (LipoCol)
38 Early Goal-Directed Nutrition in ICU Patients - EAT-ICU Trial Completed NCT01372176 Phase 4
39 Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy Completed NCT00851461 Phase 4 Goserelin
40 Assessing the Role of "Statin" Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery Completed NCT00656292 Phase 4 Simvastatin;Placebo
41 Relation Between Intrabdominal Pressure and Collapsibility Index of Inferior Vena Cava Before and After Fluid Therapy Completed NCT01553422 Phase 4
42 Long Term Effectiveness of Trigger Finger Injections With Triamcinolone vs. Dexamethasone Completed NCT03641508 Phase 4 Triamcinolone;Dexamethasone
43 Shockwave Therapy of Chronic Achilles Tendinopathy Completed NCT00958620 Phase 4
44 "NSAIDs in Acute Achilles Tendinopathy: Effect on Pain Control, Leg Stiffness and Functional Recovery in Athletes" Completed NCT00792376 Phase 4 etoricoxib;diclofenac
45 The Value of Platelet-Rich Plasma in Chronic Midportion Achilles Tendinopathy: a Double-blind Randomized Clinical Trial Completed NCT00761423 Phase 4
46 Achilles Tendinosis Study; Comparison of Radiofrequency to Surgical MicroDebridement Completed NCT00534781 Phase 4
47 The Efficacy of Polidocanol Injections as a Treatment of Chronic Achilles. Tendinopathy Completed NCT00377910 Phase 4 Aethoxysclerol
48 Colloids in Severe Trauma Completed NCT00890383 Phase 4 tetrastarch (Voluven)
49 Discomfort and Psychosocial Difficulties in Fibromyalgia Completed NCT02078791 Phase 4 Botox infiltration
50 Strengthening Exercises for Fibromyalgia Completed NCT02063750 Phase 4

Search NIH Clinical Center for Muscle Tissue Disease

Genetic Tests for Muscle Tissue Disease

Anatomical Context for Muscle Tissue Disease

MalaCards organs/tissues related to Muscle Tissue Disease:

41
Brain, Eye

Publications for Muscle Tissue Disease

Variations for Muscle Tissue Disease

Expression for Muscle Tissue Disease

Search GEO for disease gene expression data for Muscle Tissue Disease.

Pathways for Muscle Tissue Disease

GO Terms for Muscle Tissue Disease

Cellular components related to Muscle Tissue Disease according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 Z disc GO:0030018 9.63 CAPN3 DMD FBXO32 RYR1 SMN1 SMN2
2 filopodium GO:0030175 9.56 DAG1 DMD MTM1 UTRN
3 I band GO:0031674 9.54 MTM1 RYR1
4 T-tubule GO:0030315 9.54 CAPN3 DYSF RYR1
5 costamere GO:0043034 9.52 DAG1 DMD
6 SMN-Sm protein complex GO:0034719 9.51 SMN1 SMN2
7 filopodium membrane GO:0031527 9.49 DMD UTRN
8 Gemini of coiled bodies GO:0097504 9.48 SMN1 SMN2
9 SMN complex GO:0032797 9.46 SMN1 SMN2
10 contractile ring GO:0070938 9.43 DAG1 UTRN
11 dystroglycan complex GO:0016011 9.4 DAG1 SGCA
12 dystrophin-associated glycoprotein complex GO:0016010 9.35 DAG1 DMD FKRP SGCA UTRN
13 sarcolemma GO:0042383 9.28 CLCN1 DAG1 DMD DYSF FKRP LAMA2
14 cytoplasm GO:0005737 10.2 CAPN3 DAG1 DMD EMD FBXO32 GNE

Biological processes related to Muscle Tissue Disease according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 muscle contraction GO:0006936 9.7 CLCN1 DYSF EMD PABPN1 RYR1 SGCA
2 skeletal muscle tissue regeneration GO:0043403 9.65 DAG1 DMD DYSF MSTN SGCA
3 muscle cell cellular homeostasis GO:0046716 9.62 CAPN3 DMD MSTN MTM1
4 negative regulation of protein kinase B signaling GO:0051898 9.54 DAG1 MSTN MTM1
5 import into nucleus GO:0051170 9.51 SMN1 SMN2
6 response to muscle activity GO:0014850 9.49 CAPN3 MSTN
7 protein O-linked mannosylation GO:0035269 9.48 FKRP FKTN
8 muscle fiber development GO:0048747 9.46 DMD DYSF
9 DNA-templated transcription, termination GO:0006353 9.43 SMN1 SMN2
10 Schwann cell differentiation GO:0014037 9.4 DAG1 LAMA2
11 response to denervation involved in regulation of muscle adaptation GO:0014894 9.35 DAG1 DMD FBXO32 SGCA UTRN
12 muscle organ development GO:0007517 9.23 CAPN3 DMD EMD FKTN LAMA2 MSTN

Molecular functions related to Muscle Tissue Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 actin binding GO:0003779 9.62 DAG1 DMD EMD UTRN
2 structural constituent of muscle GO:0008307 9.33 CAPN3 DAG1 DMD
3 vinculin binding GO:0017166 9.13 DAG1 DMD UTRN
4 dystroglycan binding GO:0002162 8.8 DAG1 DMD FKRP
5 protein binding GO:0005515 10.19 CAPN3 CLCN1 DAG1 DMD DYSF EMD

Sources for Muscle Tissue Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....